Does Ondansetron Work in Hyperemesis of Pregnancy?
Yes, ondansetron is safe and effective for treating hyperemesis gravidarum and should be used as a second-line antiemetic when first-line agents (antihistamines, phenothiazines, or doxylamine/pyridoxine) fail to control symptoms 1.
Treatment Algorithm
First-Line Therapy
Start with antihistamines (H1 blockers), phenothiazines, or doxylamine/pyridoxine (Xonvea®) as initial antiemetics 1. These have established safety and efficacy data for nausea and vomiting in pregnancy.
Second-Line Therapy: Ondansetron
When first-line agents are ineffective, ondansetron should be prescribed without hesitation 1. The 2024 BJOG guideline explicitly states that "its use as a second-line antiemetic should not be discouraged" 1.
Efficacy Evidence
The evidence for ondansetron's effectiveness is mixed but generally supportive:
Recent placebo-controlled trial (2025): Ondansetron showed a non-significant reduction in PUQE scores compared to placebo (difference -0.51,95% CI -2.32 to 1.30) 2. While not statistically significant, this was a small trial (n=18 ondansetron vs n=20 placebo).
Comparative effectiveness: A 2014 randomized trial demonstrated ondansetron performed similarly to metoclopramide for antiemetic effects, with better tolerability—less drowsiness (12.5% vs 30%), less dry mouth (10% vs 24%), and less persistent ketonuria (12.5% vs 30%) 3. A 2022 meta-analysis confirmed no significant difference in efficacy between ondansetron and metoclopramide 4.
Older data: A 1996 pilot study found ondansetron offered no advantage over promethazine 5, though this was a small preliminary investigation.
Critical Safety Counseling
Women can be reassured about a very small absolute increase in orofacial cleft risk with first-trimester ondansetron use, which must be balanced against the substantial risks of poorly managed hyperemesis gravidarum 1.
The Cleft Palate Data
The FDA label and guideline acknowledge inconsistent findings 6:
- One large US Medicaid study showed increased oral cleft risk with oral ondansetron (RR 1.24,95% CI 1.03-1.48) but NOT with IV ondansetron (RR 0.95% CI 0.63-1.43) 6
- Two case-control studies reported conflicting associations with isolated cleft palate (OR 1.6 vs 0.5) 6
- The absolute risk increase is very small, and the timing of exposure relative to palate formation (weeks 6-9) is often uncertain 6
No Increased Risk for Other Outcomes
- No association with overall major congenital malformations 6
- Cardiovascular defect data are inconsistent (RR range 0.97-1.62) 6
- Reduced risk of spontaneous abortion compared to no antiemetic use (adjusted HR 0.82,95% CI 0.73-0.91) 7
- No increased risk of stillbirth 7
Practical Prescribing
Dosing: Standard dosing is 4-8 mg every 8 hours orally 1, 3. The guideline recommends combinations of different antiemetics for women who don't respond to single agents 1.
Route consideration: Given the potential signal for oral clefts with oral but not IV ondansetron in one large study 6, consider IV administration when feasible in the first trimester, though this finding requires confirmation.
Alternative if ondansetron fails: Metoclopramide is equally effective and safe, though it carries extrapyramidal side effect risk and should be given as slow IV bolus over ≥3 minutes 1. Recent data suggest mirtazapine may be more effective than ondansetron, showing significant PUQE score reduction versus placebo (difference -1.86, P=0.04) 2.
Common Pitfall
Do not withhold ondansetron due to cleft palate concerns. The risks of untreated severe hyperemesis gravidarum—including maternal malnutrition, Wernicke's encephalopathy, electrolyte disturbances, and psychological distress potentially leading to pregnancy termination—far outweigh the very small absolute increase in orofacial cleft risk 1, 8.